Kukje Pharma Co., Ltd. (KRX:002720)

South Korea · Delayed Price · Currency is KRW

3,430.00

+85.00 (2.54%)

Nov 2, 2026, 3:30 PM KST

Market Cap	72.58B -17.7%
Revenue (ttm)	181.27B +8.0%
Net Income	5.00B -21.5%
EPS	240.38 -23.3%
Shares Out	21.16M
PE Ratio	14.27
Forward PE	n/a
Dividend	30.00 (0.87%)
Ex-Dividend Date	Mar 12, 2026

Volume	304,746
Open	3,265.00
Previous Close	3,345.00
Day's Range	3,265.00 - 3,450.00
52-Week Range	2,810.00 - 5,470.00
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Kukje Pharma

Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAID... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1959

Employees 267

Stock Exchange Korea Stock Exchange

Ticker Symbol 002720

Full Company Profile

Financial Performance

In 2025, Kukje Pharma's revenue was 175.50 billion, an increase of 12.16% compared to the previous year's 156.46 billion. Earnings were 5.70 billion, an increase of 9.46%.

Financial Statements